Valeant Pharma (VRX) Announces Filing of 10-K for FY15

Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray

Piper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:

Wholesaler inventory... More

BMO Capital 'Incrementally Positive' on Valeant (VRX) 10K, But Notes Important Changes in Fundamentals

BMO Capital analyst Alex Arfaei weighed in Valeant Pharmaceuticals (NYSE: VRX) after the 10K. He said it was incrementally positive, although notes important change in fundamentals.

Arfaei commented, "Valeant is now in compliance of its debt agreements, and should avert technical default on its debt. As far as we can tell, the new restatement is related to 4Q15, and it is modest. 4Q15 revenue is now $21MM lower because of Addyi and Xifaxan adjustments, this brings non-GAAP EPS down from $2.50 to $2.40 under the... More

Valeant Pharma (VRX) Resumes Trading

Valeant Pharma (NYSE: VRX) shares resume trading. The stock was up around 2 percent, but is now about flat.

Valeant Pharma (VRX) Announces Nominees For Election to Board

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016.

As announced on April 25, 2016, Joseph C. Papa has been named Valeant's Chairman and Chief Executive Officer. Mr. Papa has been nominated for election to the Board, along with Robert A. Ingram, Robert N. Power and five of the current independent directors who were appointed to the Board in the last year: William A. Ackman, Dr. Frederic Eshelman, Stephen... More

Valeant Pharma (VRX) More Pain Coming - Mizuho

Mizuho analyst, Irina Koffler, sees price cuts, divestitures & generic erosion coming for Valeant Pharma (NYSE: VRX). No change to the Underperform rating or $18 PT.

A lot of news came out during the Senate's Special Committee on Aging.

1) five Directors are stepping down from the Board. These conveniently include three of the four Ad-Hoc Committee members (including... More

Valeant Pharma (VRX) Details Compensation for Incoming CEO Papa, Outgoing CEO Pearson

Valeant Pharma (NYSE: VRX) disclosed teh following late Thursday:

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Joseph C. Papa -- New Chairman and CEO

On April 25, 2016, the Board of Directors (the Board) of Valeant Pharmaceuticals International, Inc. (Valeant or the Company) announced the appointment of Joseph C. Papa to become Valeants Chairman and Chief Executive Officer. Mr. Papa, is expected to join the Company by early May and will succeed J.... More

Valeant to name four new directors as soon as Friday: WSJ

(Reuters) - Drugmaker Valeant Pharmaceuticals International Inc (NYSE: VRX) is expected to name four new directors as soon as Friday, the Wall Street Journal reported.

Five of its long-standing directors, including activist firm ValueAct's Mason Morfit, have agreed to step down to make room for... More

Bill Ackman says that he expects Valeant Pharma (VRX) to file its 10k by Friday

Bill Ackman says that he expects Valeant Pharma (NYSE: VRX) to file its 10k by Friday

Pershing Square's Ackman pledges to ensure Valeant (VRX) won't hike drug prices again - Bloomberg

Pershing Square's BIll Ackman says that Valeant Pharma (NYSE: VRX) is seeking ways of setting appropriate drug prices, according to Bloomberg. The investor pledges to ensure Valeant won't hike drug prices again.

UPDATE - Ackman said that a balance is needed between... More

Ackman, Valeant pledge reforms after spiking drug prices

By Sarah N. Lynch and Bill Berkrot

WASHINGTON/NEW YORK (Reuters) - Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals (NYSE: VRX) to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.

Speaking before the Senate Special Committee on Aging, Ackman revealed that Valeant's board will hold a conference call on Thursday to discuss the costs of heart medications Isuprel and Nitropress, as well as Cuprimine and Syprine, two drugs... More